Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo
- 27 February 2008
- journal article
- Published by Elsevier BV in Life Sciences
- Vol. 82 (9-10), 536-541
- https://doi.org/10.1016/j.lfs.2007.12.014
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Decreased hepatocyte membrane potential differences and GABAa-β3 expression in human hepatocellular carcinomaHepatology, 2007
- γ-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP–Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 PathwayCancer Research, 2005
- A new role for GABA: inhibition of tumor cell migrationTrends in Pharmacological Sciences, 2003
- Urine GABA levels in ovarian cancer patients:: elevated GABA in malignancyCancer Letters, 2001
- Increased GABAergic activity inhibits α-fetoprotein mRNA expression and the proliferative activity of the HepG2 human hepatocellular carcinoma cell lineJournal of Hepatology, 2000
- Role of Heteromer Formation in GABA B Receptor FunctionScience, 1999
- Cloning and Tissue Distribution of Novel Splice Variants of the Rat GABABReceptorBiochemical and Biophysical Research Communications, 1998
- Effect of selective and non-selective muscarinic blockade on baclofen inhibition of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar ratsCarcinogenesis: Integrative Cancer Research, 1996
- p21 is a universal inhibitor of cyclin kinasesNature, 1993
- Attenuation by the GABA Receptor Agonist Baclofen of Experimental Carcinogenesis in Rat Colon by AzoxymethaneOncology, 1992